Telomir Pharmaceuticals (TELO) to Release Earnings on Monday

Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) is anticipated to announce its earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.05). On average, analysts expect Telomir Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Telomir Pharmaceuticals Trading Down 1.2 %

Telomir Pharmaceuticals stock traded down $0.03 during midday trading on Friday, hitting $2.49. The stock had a trading volume of 105,442 shares, compared to its average volume of 132,841. Telomir Pharmaceuticals has a 52-week low of $2.35 and a 52-week high of $8.40. The company has a market capitalization of $74.11 million, a PE ratio of -4.29 and a beta of 0.17. The firm's fifty day moving average is $3.26 and its two-hundred day moving average is $4.08.

Hedge Funds Weigh In On Telomir Pharmaceuticals

An institutional investor recently raised its position in Telomir Pharmaceuticals stock. Bank of America Corp DE lifted its position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO - Free Report) by 283.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,713 shares of the company's stock after purchasing an additional 10,880 shares during the quarter. Bank of America Corp DE's holdings in Telomir Pharmaceuticals were worth $61,000 at the end of the most recent reporting period.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on TELO. RODMAN&RENSHAW upgraded shares of Telomir Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, February 20th. Rodman & Renshaw assumed coverage on Telomir Pharmaceuticals in a research note on Friday, February 21st. They issued a "buy" rating and a $15.00 price objective for the company.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.